# Braveheart Bio Inc. (BRVE) fundamentals

Data as of 2026-11-05. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $17.00, market value $1.5 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Braveheart Bio Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.

## Dividends
- **Dividend: none**. Braveheart Bio Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (4 analysts). 4 analysts cover Braveheart Bio Inc.; the consensus is strong_buy, with an average price target of $45.25 (+166% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **From 52-week high: -46.9%** (0.0% above the low). Trading 47% below its 52-week high, deep in a drawdown.
- **RSI (14-day): 42**. An RSI of 42 is neutral.
- **Beta (1 yr): -0.33** (volatility 80%). Beta of -0.33 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=BRVE · Page: https://foliofundamentals.com/stocks/brve

Not investment advice.